Clinical Trial: NCT02608216
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | University of Pennsylvania |
| Information Provided By: | University of Pennsylvania |
| Last Update Posted: | 2026-10-07 |
Study Overview
Brief Summary
In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT).
Official Title
[18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy
Conditions
Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
Intervention / Treatment
- Drug: [18F]FLT
- Device: PET/CT
- Drug: ribociclib
- Drug: paclitaxel
Other Study ID Numbers
- 822997
Start Date
2015-11
Primary Completion Date (Estimated)
2026-11
Study Completion Date (Estimated)
2026-11
Enrollment (Estimated)
20
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | University of Pennsylvania |
| Information Provided By: | University of Pennsylvania |
| Last Update Posted: | 2026-10-07 |
Study Overview
Brief Summary
In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT).
Official Title
[18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy
Conditions
Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
Intervention / Treatment
- Drug: [18F]FLT
- Device: PET/CT
- Drug: ribociclib
- Drug: paclitaxel
Other Study ID Numbers
- 822997
Start Date
2015-11
Primary Completion Date (Estimated)
2026-11
Study Completion Date (Estimated)
2026-11
Enrollment (Estimated)
20
Study Type
Interventional
Phase
Phase 1